Protective Role of Programmed Death 1 Ligand 1 (PD-L1)in Nonobese Diabetic Mice : The Paradox in Transgenic Models by Wang, Chia-Jen et al.
Protective Role of Programmed Death 1 Ligand 1
(PD-L1) in Nonobese Diabetic Mice
The Paradox in Transgenic Models
Chia-Jen Wang,
1 Feng-Cheng Chou,
1 Chi-Hong Chu,
2 Jen-Chine Wu,
1 Shih-Hua Lin,
3
Deh-Ming Chang,
3 and Huey-Kang Sytwu
1,4,5,6
OBJECTIVE—Coinhibitory signals mediated via programmed
death 1 (PD-1) receptor play a critical role in downregulating
immune responses and in maintaining peripheral tolerance.
Programmed death 1 ligand 1 (PD-L1), the interacting ligand for
PD-1, widely expressed in many cell types, acts as a tissue-
speciﬁc negative regulator of pathogenic T-cell responses. We
investigated the protective potential of PD-L1 on autoimmune
diabetes by transgenically overexpressing PD-L1 in pancreatic
-cells in nonobese diabetic (NOD) mice.
RESEARCH DESIGN AND METHODS—We established an
insulin promoter–driven murine PD-L1 transgenic NOD mouse
model to directly evaluate the protective effect of an organ-
speciﬁc PD-L1 transgene against autoimmune diabetes. Transgene
expression, insulitis, and diabetic incidence were characterized in
these transgenic NOD mice. Lymphocyte development, Th1 cells,
and regulatory T-cells were analyzed in these transgenic mice; and
T-cell proliferation, adoptive transfer, and islet transplantation were
performed to evaluate the PD-L1 transgene–mediated immune-
protective mechanisms.
RESULTS—The severity of insulitis in these transgenic mice is
signiﬁcantly decreased, disease onset is delayed, and the inci-
dence of diabetes is markedly decreased compared with litter-
mate controls. NOD/SCID mice that received lymphocytes from
transgenic mice became diabetic at a slower rate than mice
receiving control lymphocytes. Moreover, lymphocytes collected
from recipients transferred by lymphocytes from transgenic mice
revealed less proliferative potential than lymphocytes obtained
from control recipients. Transgenic islets transplanted in dia-
betic recipients survived moderately longer than control islets.
CONCLUSIONS—Our results demonstrate the protective po-
tential of transgenic PD-L1 in autoimmune diabetes and illustrate
its role in downregulating diabetogenic T-cells in NOD mice.
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P
rogrammed death 1 (PD-1) is an immunoreceptor
of the CD28/CTLA-4 family whose expression is
induced in activated T- and B-cells and in macro-
phages (1,2). PD-1 has two cytoplasmic tyrosine
motifs: one an immunoreceptor tyrosine-based inhibition
motif and the other an immunoreceptor tyrosine-based
switch motif (ITSM). On interaction of PD-1 with its
ligands PD-L1 (B7-H1) or PD-L2 (B7-DC), the tyrosine-
phosphorylated ITSM of PD-1 recruits a src homology 2
domain–containing tyrosine phosphatase 2, which medi-
ates the dephosphorylation signaling and reduces lympho-
cyte activation (3). PD-1
/ mice on different genetic
backgrounds develop distinct autoimmune phenotypes,
such as lupus-like glomerulonephritis/arthritis in C57Bl/6
(B6) mice or anticardiac troponin I–mediated dilated
cardiomyopathy in Balb/c mice (4,5). These observa-
tions indicate that PD-1 is a critical negative regulator of
lymphocyte activation and that the phenotype of PD-1
deﬁciency–induced autoimmunity is highly inﬂuenced
by other genetic factors.
Murine PD-L1 is expressed on many cell types, including
stromal cells within many organs, but PD-L2 expression is
much more restricted, occurring mainly in dendritic cells,
activated monocytes, and macrophages (6,7). Although
accumulating data indicate that both PD-L1/PD-1 and
PD-L2/PD-1 signals can suppress T-cell proliferation and
effector function by blocking cell cycle progression and
cytokine production, signaling through PD-L1 interaction
is more potent than that through PD-L2 (8). This is consistent
with the observations that cytokine production, cytotoxic
activity, and clonal expansion were signiﬁcantly enhanced in
T-cells and antigen-presenting cells from PD-L1
/ mice,
compared with cells from wild-type or PD-L2
/ mice (9,10).
Moreover, the PD-L1
/ mice revealed an increased suscep-
tibility to the induction of autoimmune diseases, such as
experimental allergic encephalomyelitis (9), strongly sug-
gesting a protective role of tissue PD-L1 in the maintenance
of immune tolerance. Furthermore, treatment of nonobese
diabetic (NOD) mice with a combination of agonistic
PD-L1.Ig fusion protein and monoclonal antibodies
(mAbs) to CD154 induced long-term islet allograft sur-
vival, whereas the inhibition of PD-L1–mediated signals by
blocking antibody exacerbated autoimmune diabetes (11).
Based on these ﬁndings, we hypothesize that transgenic
expression of PD-L1 in an islet-speciﬁc manner may help
in preventing T-cell–mediated islet destruction in NOD
mice.
To investigate the preventive and/or therapeutic poten-
tial of PD-L1 in autoimmune diabetes, we generated trans-
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insulin promoter. Although a recent report demonstrated
that local expression of transgenic PD-L1 on -cells of B6
mice unexpectedly promotes organ-speciﬁc autoimmunity
and transplant rejection (12), we hypothesized that over-
expression of PD-L1 on islet cells in NOD mice would
enhance inhibitory signaling through the PD-1–PD-L1 in-
teraction and protect islet cells from lymphocyte attack.
Our results demonstrate that transgenic PD-L1 on islet
cells signiﬁcantly ameliorates the severity of insulitis and
incidence of diabetes in NOD mice. Interestingly, our
results also indicate that local transgene expression not
only protects islets in situ but also mediates a peripheral
tolerance. Moreover, transgenic islets transplanted in dia-
betic recipients survived moderately longer than control
islets. Overall, we demonstrate for the ﬁrst time the
preventive potential of transgenic PD-L1 in autoimmune
diabetes and provide a theoretical basis for organ-speciﬁc
genetic manipulation for disease prevention.
RESEARCH DESIGN AND METHODS
NOD and NOD/SCID mice were purchased from The Jackson Laboratories
(Bar Harbor, ME), and all mice were subsequently bred at the animal center
of the National Defense Medical Center (Taipei, Taiwan, Republic of China)
under speciﬁc pathogen-free conditions. The spontaneous incidence of diabe-
tes in the colony was 80–90% in females and 20–30% in males by 25 weeks of
age.
Generation of PD-L1 transgenic NOD mice. The PD-L1 gene was cloned
from a cDNA library of mouse heart prepared with TRIzol and Superscript II
reverse transcriptase (Invitrogen, Carlsbad, CA). It was ampliﬁed by PCR with
the forward primer 5-TAGTTCCCAAAACATGAGGATA-3 and reverse primer
5-AGAGGGTTCAACACTGCTTAC-3. The PCR products were cloned into the
pCR3.1 vector (Invitrogen) and subsequently sequenced. The pCR3.1-PD-L1
was digested with EcoRI and subcloned into pINS plasmid for the generation
of transgenic mice (13). A modiﬁed human insulin promoter (pINS) was
provided by Dr. Miyazaki (Osaka University, Osaka, Japan). The murine PD-L1
cDNA was inserted into the pINS plasmid to generate a pINS-mPD-L1
construct. The linearized DNA fragment with the human insulin promoter and
PD-L1 cDNA was puriﬁed and microinjected into the pronuclei of NOD
embryos at the one-cell stage and then implanted into pseudopregnant
(BALB/c  FVB) F1 females. Southern blotting was performed to conﬁrm the
presence of the pINS-PD-L1 transgene. All transgenic mice used in our study
were heterozygous for the PD-L1 transgene.
Immunohistochemical analysis. The pancreas was removed from each
mouse, embedded into Tissue-Tek O.C.T. compound, and ﬁxed by acetone.
Frozen sections of each sample were incubated with rat anti-mouse PD-L1
mAb (eBioscience) followed by goat anti-rat–horseradish peroxidase (HRP),
and then stained with aminoethyl-carbazole reagent (DAKO, Carpinteria, CA)
for 10 min. A ﬂuorescent image was collected directly after treatment with
phycoerythrin-conjugated anti-mouse PD-L1 mAb, and DAPI was used for
background staining.
Assessment of insulitis and diabetes. The severity of insulitis was scored
on hematoxylin-eosin–stained sections of pancreas from mice 14–16 weeks of
age by investigators blinded to the identity of the sections. At least 50 islets
from each pancreas were randomly chosen for microscopic examination. The
severity of insulitis was classiﬁed as described previously (14). Urine glucose
concentration (glycosuria) was measured weekly or every other day using
Chemstrips (Boehringer Mannheim, Indianapolis, IN). Animals scoring posi-
tive (250 mg/dl glucose) on two consecutive tests were classiﬁed as diabetic.
T-cell proliferation and division assay. Splenocytes from 8-week-old mice
were treated with Tris-buffered ammonium chloride to eliminate the erythro-
cytes, washed, and resuspended at a concentration of 5  10
6 cells/ml in RPMI
1640. Cells were stimulated with immobilized anti-CD3 antibody (BD Pharm-
ingen), mouse PD-L1.Ig, or control human IgG1.Ig (R&D Systems). The
incorporation of [
3H]methyl thymidine was detected at 72 h with a TopCount
liquid scintillation counter (Packard). For assessment of cell division, spleno-
cytes were labeled with 5 mol/l carboxyﬂuorescein succinimidyl ester
(CFSE) solution at room temperature for 5 min and washed three times in PBS
containing 5% FBS by centrifugation at room temperature.
Adoptive transfer. Splenocytes of female transgenic or nontransgenic NOD
donors were treated with Tris-buffered ammonium chloride for erythrocyte
depletion, and 2  10
7 cells were injected into female NOD/SCID mice via the
retro-orbital plexus. Diabetes was assessed as described above. In another
experiment using the procedure described above, 6-week-old female trans-
genic NOD mice or their nontransgenic control littermates were selected as
recipients and injected with 2  10
7 cells from 12-week-old female NOD
donors.
Isolation of islet-inﬁltrated lymphocytes. Pancreata were collected from
16- to 20-week-old transgenic or control NOD mice. Islets were isolated by
collagenase digestion and Histopaque gradient puriﬁcation. Marginal cells
were collected and incubated with Cell Dissociation Buffer (Gibco). After
passing over a cell strainer, suspended single cells were counted and stained
with anti-mouse CD3 antibody for ﬂow cytometric analysis. The percentage of
inﬁltrated CD3
 cells in islets was obtained by gating on lymphocytes.
Flow cytometry. Lymphocytes from spleen or pancreatic lymph node (PLN)
were stained with anti-mouse CD4, CD8, CD19, CD25, Foxp3 (BD Pharmin-
gen), anti-mouse PD-1, PD-L1 (eBioscience), anti-human CD90 (hThy1, clone
5E10), and anti-mouse CD90.1 (mThy1.1, clone OX-7) (BD Pharmingen).
CFSE-labeled lymphocytes were analyzed by triple staining with anti-mouse
CD4 and CD8 antibodies. Flow cytometric analysis was performed with a
FACSCalibur (BD Biosciences, San Diego, CA).
Islet transplantation. Regular NOD and PD-L1 transgenic mice at 6–8
weeks of age were used as donors for islet transplants. Newly diabetic female
NOD mice with blood glucose concentrations between 300 and 500 mg/dl were
collected as recipients. Islets were isolated by collagenase digestion and
Histopaque gradient puriﬁcation. Marginal islets with diameters between 20
and 75 m were handpicked, and a total of 700 islets were implanted to the left
renal capsule of recipient mice. Blood glucose concentrations of recipients
were monitored daily. Loss of graft function was deﬁned as a blood glucose
result of 300 mg/dl in two consecutive evaluations.
RESULTS
Expression of PD-1 and the inhibitory effect of PD-L1
on NOD T-cells. To investigate the interactive role of
PD-1 and PD-L1 in the regulation of autoimmune diabetes
in NOD mice, we ﬁrst determined the expression of PD-1
on NOD lymphocytes and evaluated the inhibitory poten-
tial of PD-L1. Our results indicated that 	1% of spleno-
cytes freshly isolated from 8-week-old female NOD or
BALB/c mice expressed PD-1 (data not shown), suggesting
a very low PD-1 expression on resting splenocytes in both
strains. However, 48 h after anti-CD3 stimulation, the
percentage of PD-1
 splenocytes increased to 50.34% (Fig.
1A, left), consistent with previous reports that PD-1 is
upregulated after T-cell receptor (TCR) stimulation (1,15),
and 72 h after stimulation, the percentage of PD-1
 cells
reached 65.90% (Fig. 1A, right), suggesting an increase of
PD-1 dependence on activation status. Interestingly, the
increase in numbers of PD-1
 CD4
 T-cells (37.81 and
41.29% at 48 and 72 h, respectively) after stimulation is
much less signiﬁcant than that of CD8
 T-cells (84.58 and
92.16% at 48 and 72 h, respectively), suggesting a relative
inability of CD4
 T-cells to induce PD-1 on activation.
To investigate whether ligand binding to PD-1 can
downregulate the activation status of NOD lymphocytes,
we coated recombinant PD-L1.Ig on culture plates and
measured the proliferation level of anti-CD3–stimulated
lymphocytes. Our results clearly indicate a dose-depen-
dent inhibition of proliferation of NOD lymphocytes by
PD-L1.Ig (Fig. 1B), and they support the hypothesis that
additional PD-1 signaling provided by coated PD-L1 can
effectively downregulate NOD lymphocyte activation and
proliferation. Therefore, we generated PD-L1 transgenic
NOD mice and investigated whether -cell–speciﬁc trans-
gene expression could mediate protection in autoimmune
diabetes.
Generation of PD-L1 transgenic NOD mice. To directly
evaluate the protective effect of an organ-speciﬁc PD-L1
transgene against autoimmune diabetes, we established an
insulin promoter–driven murine PD-L1 (pINS-mPD-L1)
transgenic NOD mouse model. The pINS-mPD-L1 con-
struct contains the insulin promoter, the ﬁrst and part of
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rabbit -globin, mouse PD-L1 cDNA, and a poly-A signal
from rabbit -globin (Fig. 2A). The insulin promoter is
highly speciﬁc to -cells and leads to signiﬁcant transgene
production (13,16). To speciﬁcally determine the level of
transcription of the PD-L1 transgene and to distinguish it
from endogenous PD-L1, we designed a P1 primer to bind
to the second exon of the insulin gene and a P3 primer to
bind the 3 end of the coding region of PD-L1. The total
expression of endogenous and transgenic PD-L1 was de-
tected by a P2 primer binding to the 5 end of the coding
region of PD-L1 and P3 (Fig. 2A). To test potential
expression of pINS-mPDL1 transgene in NOD -cells, we
transfected this construct into the NIT-1 cell line, an NOD
insulinoma, and detected its expression by immunocyto-
chemistry (ICC) (Fig. 2B) and ﬂow cytometry (Fig. 2C).
NIT-1 cells transfected with pINS-mPD-L1 revealed a
strong PD-L1 signal detected by ICC (Fig. 2B), consistent
with the ﬂow cytometric data that 88% of cells are PD-L1

compared with 7.6% of control cells (Fig. 2C). These
results clearly demonstrate the expressional availability
and feasibility of pINS-mPDL1 construct in NOD -cells.
We therefore microinjected this construct into fertilized
NOD eggs to generate the pINS-mPDL1 transgenic mice.
One of the transgenic lines obtained, denoted as L1C,
was characterized. Southern blot analysis revealed one to
ﬁve copies of the transgene in the L1C genome (Fig. 3A).
The expression of transgenic PD-L1 was detected by
RT-PCR with transgene-speciﬁc P1 and P3 primers. Our
results demonstrate that transgenic PD-L1 was speciﬁcally
expressed in pancreas in L1C mice (Fig. 3B), indicating the
FIG. 1. Expression of PD-1 and the inhibitory effect of PD-L1 on NOD
T-cells. A: Splenocytes from 8-week-old female NOD mice were cul-
tured in plates coated with 2 g/ml anti-CD3 antibody for 48 (left)o r
72 (right) hours. The stimulated cells were then stained with anti–PD-1
antibody (ﬁlled region), and the negative control of unstained cells is
indicated as a dotted line. Percentages of PD-1
 cells in CD4 and CD8
populations (middle and bottom panels, respectively) are shown in the
top right corner of the histograms. B: Splenocytes were cultured in
plates coated with 2 g/ml anti-CD3 antibody and 2.5 or 5 g/ml
PD-L1.Fc or control IgG1.Fc. Cells were pulsed with 5 Ci/ml [
3H]thy-
midine at 60 h, and the incorporation was measured at 72 h by
scintillation counting.
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FIG. 2. Construction and expression of murine PD-L1. A: Schematic
diagram of the whole transgene construct. The black areas represent
exons, and the gray areas represent introns. The entire ﬁrst noncoding
exon followed by the ﬁrst intron and 16 bp of the second exon of human
insulin gene, which are not translated into protein, were preserved to
ensure the stringency of the insulin promoter. A forward primer in the
second exon of the insulin gene (P1) and a backward primer in the
coding region of mouse PD-L1 (P3) were designed to speciﬁcally
evaluate PIns-mPD-L1 transcription. The total PD-L1 transcription can
be detected by P2 and P3 primers. NIT-1 cells were transfected with
PIns-mPD-L1 (right) or control plasmid (left). Cells were then stained
by anti–PD-L1 antibody to detect the PD-L1 expression by ICC (B) and
ﬂow cytometry (C). Solid histogram indicates NIT-1 transfectants
stained with anti–PD-L1 antibody, and dotted line indicates unstained
transfectants.
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indicate that in normal NOD mice, endogenous PD-L1
detected by P2 and P3 primers is highly expressed in
several organs including thymus, heart, and spleen, but
that the signal is very low in pancreas (Fig. 3B). High
expression of PD-L1 in lymphoid organs suggests a critical
role of PD-L1 in the induction and maintenance of immune
tolerance, consistent with previous reports of the auto-
immune phenotypes developed in PD-L1 knockout mice
(9). To evaluate the expression of transgenic or endoge-
nous PD-L1 at the protein level, we performed immunoﬂu-
orescent (Fig. 3C, top) and immunohistochemical (Fig. 3C,
middle) analyses on pancreatic sections from L1C (Fig.
3C, right) or NOD (Fig. 3C, left) mice. The results conﬁrm
that, consistent with the RT-PCR results, transgenic PD-L1
is highly expressed on pancreatic islets (Fig. 3C, right side
of middle panel) in L1C mice, whereas the pancreatic
expression of endogenous PD-L1 is very low (Fig. 3C, left
side of middle panel) in control littermates (Fig. 3B).
Expression patterns of insulin between L1C and NOD mice
are very similar, suggesting that transgenic PD-L1 does not
alter the insulin expression in L1C mice (Fig. 3C, bottom).
Thus, we successfully generated L1C transgenic NOD mice
in which the transgenic PD-L1 is overexpressed in an
islet-speciﬁc manner.
Characterization of the diabetogenic process in L1C
mice. To investigate the protective effects of organ-
speciﬁc and membrane-bound expression of transgenic
PD-L1 in autoimmune diabetes, we analyzed the severity
of insulitis and the incidence of spontaneous diabetes in
L1C mice. Although expression of the transgene did not
completely prevent the development of insulitis, the sever-
ity of insulitis in L1C mice was signiﬁcantly reduced (Fig.
4A). Around 50% of islets from L1C mice were free from
lymphocytes compared with 20% in controls (P 	 0.05);
and only 5% islets from L1C showed destructive insulitis
compared with 20% in controls (P 	 0.05). In addition to
histological analysis of insulitis, we further assessed the
lymphocyte composition of the inﬁltrates within the islet
by ﬂow cytometry. Our result indicates that the percentage
of CD3 T-cells in L1C islets is signiﬁcantly decreased
compared with control islets (26 vs. 36%, P 	 0.05; Fig.
4B). To further investigate the protective efﬁcacy of trans-
genic PD-L1, we analyzed spontaneous and lymphocyte
transfer diabetes in L1C mice. Compared with control
littermates, which started to develop diabetes at 11 weeks
of age, the ﬁrst L1C mouse became diabetic after 14
weeks, indicating a delay in onset of disease. At around 20
weeks of age, the diabetic incidence of control mice
increased to 64%, but the incidence in L1C mice was only
10.8%. After 25 weeks, 88% of control mice developed
diabetes, but the incidence in L1C mice was only 21.6%
(Fig. 4C), demonstrating that transgenic PD-L1 signiﬁ-
cantly inhibits the development of autoimmune diabetes
in NOD mice (P 	 0.01). Because it is possible that the
protection seen in L1C mice is due to modulation of the
development of autoreactive T-cells by transgenic ex-
pression of PD-L1, we performed adoptive transfer
experiments to further investigate whether PD-L1 over-
expression can also protect mice from lymphocyte
transfer–induced diabetes. Six-week-old female L1C
mice were injected intravenously with 2  10
7 spleno-
cytes isolated from 12-week-old female NOD mice.
Around 60% of control mice developed diabetes 60 days
after transfer, but L1C recipients remained diabetes free
until 80 days (Fig. 4D), suggesting that islet-speciﬁc
FIG. 3. Generation of PD-L1 transgenic NOD mice. A: Southern blot analysis identiﬁed the transgenic PD-L1 signal in one of the founders, denoted
as L1C, and provided the relative copy number of the PD-L1 transgene in the L1C line. B: Islet-speciﬁc expression of the PD-L1 transgene was
conﬁrmed by RT-PCR analysis. The spliced transgenic PIns-mPD-L1 and endogenous PD-L1 transcripts from multiple organs of L1C (top)o r
regular NOD (bottom) mice were assessed. HGPRT transcription served as internal control. C: Frozen pancreatic sections of 6-week-old control
NOD (left) or L1C (right) mice were stained with phycoerythrin-conjugated anti–PD-L1 antibody and then observed on a ﬂuorescent microscope.
DAPI was used as background staining (top). Immunohistochemical analysis was performed using anti–PD-L1 (middle) or anti-insulin (bottom)
and HRP-conjugated secondary antibody (bottom).
.
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of spontaneous diabetes but also protects mice from
pathogenic lymphocyte transfer–mediated diabetes.
One of the most stringent ways to test whether over-
expression of PD-L1 could protect -cells against immune
attack is to examine whether transgenic islet grafts could
reverse hyperglycemia in diabetic NOD mice. We isolated
islets from L1C mice and transplanted them into kidney
capsules of diabetic NOD recipients. Although transgenic
islets survived longer than wild-type islets, the result is not
statistically signiﬁcant (7.9 and 6.1 days, respectively, P 

0.06; Table 1), suggesting that expression of transgenic
PD-L1 was partially effective in prolonging islet graft
survival but did not provide complete protection from
diabetes recurrence.
Lymphocyte development and the antidiabetogenic
mechanism in L1C mice. It has been well characterized
that an imbalance between Th1 and Th2 responses predis-
poses NOD mice to developing autoimmune diabetes (17).
To investigate whether the protective effect of transgenic
PD-L1 works through regulating Th1 and Th2 development
in L1C mice, we crossed L1C transgenic mice with T1 and
T2 double transgenic NOD mice to generate PD-L1/T1/T2
triple transgenic mice. T1 and T2 double transgenic mice
bear two transgenes: human Thy1 (hThy1) under control
of the murine interferon- (IFN-) promoter and murine
Thy1.1 (mThy1.1) under control of the murine interleu-
kin-4 (IL-4) promoter (18). Using these PD-L1/T1/T2 triple
transgenic mice, we can directly measure the levels of Th1
and Th2 cells by detecting the expression of hThy1 (Th1
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FIG. 4. Characterization of the diabetogenic process of PD-L1 transgenic mice. A: The insulitis scores were measured in seven mice of each group
at 14–16 weeks old. B: The CD3 T-cells inﬁltrated in the pancreatic islets of L1C (Œ) or control littermates (f) were analyzed by ﬂow cytometry.
C: Spontaneous diabetes in female L1C (F, 37 mice) or their control littermates (E, 25 mice) was monitored by weekly measurement of
glycosuria. D: The incidence of diabetes in L1C mice or control littermates adoptively transferred with splenocytes from 12-week-old female NOD
mice was monitored by testing every other day for glycosuria.
TABLE 1
Transgenic PD-L1 moderately prolongs the survival period of
grafts in isogenic islet transplantation
Donor
islets
Graft survival of
each recipient (days)
Mean survival
period (days)
NOD 5, 5, 5, 6, 6, 6, 7, 9 6.1
L1C 5, 6, 7, 7, 7, 9, 9, 13 7.9
Pancreatic islets isolated from 6- to 8-week-old mice were trans-
planted into recipients that were newly diagnosed with diabetes.
Blood glucose concentration of recipients was monitored every day.
The recurrence of diabetes among the recipients was deﬁned as a
recipient blood glucose concentration 16.7 mmol/l in two consec-
utive evaluations. The day of diabetic recurrence was considered as
the end of islet survival.
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absolute cell numbers and distribution of each lymphocyte
subpopulation in spleen (Fig. 5A, top) or PLNs (Fig. 5A,
bottom) are similar between PD-L1/T1/T2 triple (Fig. 5A,
gray bar) and T1/T2 double (Fig. 5A, black bar) transgenic
mice, indicating that local expression of transgenic PD-L1
does not alter systemic lymphocyte development in NOD
mice. Moreover, the number and percentage of IFN-–
producing (hThy1
) or IL-4–producing (mThy1.1
) cells
in spleen or PLN in PD-L1/T1/T2 triple transgenic mice
were not different from those in T1/T2 double transgenic
mice, suggesting that transgenic PD-L1 in islets does not
suppress systemic IFN-–producing cells or induce IL-4–
producing cells.
It has also been reported that NOD mice have a relative
deﬁciency in CD4
25
 regulatory T-cells (Tregs), leading
to an inability to maintain peripheral tolerance (19). To
investigate whether transgenic PD-L1 can enhance the
development of these Tregs and thus protect L1C mice
from autoimmune diabetes, we analyzed the number and
percentage of CD4
25
Foxp3 cells in transgenic mice.
L1C mice (Fig. 5B, bottom) and control littermates (Fig.
5B, top) exhibited similar numbers and percentages of
CD4
25
Foxp3 cells in spleen (Fig. 5B, left) and PLN (Fig.
5B, right), indicating that transgenic PD-L1 is not likely to
increase the population of Tregs. These results also sug-
gest that genetic manipulation of immune responses in an
organ-speciﬁc manner is not likely to induce the systemic
development of Tregs.
To further investigate the protective mechanism of
transgenic PD-L1, we performed adoptive transfer exper-
iments and functionally characterized the pathogenicity of
T-cells in L1C mice. NOD/SCID recipients were injected
intravenously with L1C or control splenocytes and the
diabetic processes in the two groups were compared. In
recipients of splenocytes from nontransgenic littermates,
diabetes developed at 32 days after injection, whereas
recipients of splenocytes from L1C mice developed dis-
ease at day 52. At day 60, all recipients of control cells had
developed disease, whereas the disease incidence in recip-
ients of L1C splenocytes was only 23.5%, although after
this time, recipients of L1C splenocytes rapidly developed
diabetes, and the incidence reached 90% at day 100 (Fig.
6A). These results indicate an impairment of L1C spleno-
cytes in disease induction and suggest a potential role of
transgenic PD-L1 in regulating autoimmunity in NOD mice.
To further characterize the proliferation of L1C lympho-
cytes, we stimulated those cells with anti-CD3 or ConA. By
CFSE-labeling experiments, we demonstrated that anti-
CD3–stimulated L1C lymphocytes, both CD4 and CD8,
divided much more slowly than control lymphocytes (Fig.
6B). Further analyses on lymphocytes isolated from NOD/
SCID recipients also indicate that L1C lymphocytes were
less proliferative and divided more slowly than control
lymphocytes (Fig. 6C), consistent with the observation
that L1C lymphocytes induced disease in recipients with a
slower time course (Fig. 6A).
DISCUSSION
PD-1 knockout mice in different genetic backgrounds
develop various autoimmune diseases, not only indicating
that negative costimulation via PD-1 is essential to down-
regulate inappropriate immune responses, such as autoim-
munity and sustained inﬂammation, but also suggesting
that PD-1 deﬁciency may exaggerate the genetic predispo-
sition of autoimmune diseases, such as type 1 diabetes,
rheumatoid arthritis, or lupus. PD-L1 acts as a tissue-
speciﬁc negative regulator of pathogenic T-cell responses.
Our result that PD-L1 is highly expressed in lymphoid
organs, such as thymus, spleen, and lymph nodes, sup-
ports a critical role of PD-L1 in the induction and mainte-
nance of immune tolerance, also consistent with previous
reports of the autoimmune phenotypes developed in
PD-L1 knockout mice (9). Moreover, the observation in
our study that heart expresses high levels of PD-L1 may be
linked to the abnormal phenotype in mice that develop
fatal autoimmune cardiomyopathy due to a lack of PD-1
signaling (5).
In contrast to our results in L1C mice, it has recently
been reported that expression of a rat insulin promoter-
driven PD-L1 transgene in mice on a B6 background
unexpectedly enhanced T-cell priming and effector func-
tion and promoted autoimmunity (12). Based on the
discrepancy between these two models, we propose that
inhibitory regulation by PD-1/PD-L1 interactions may be
highly dependent on the genetic background of mouse
strains. This is supported by development of distinct
autoimmune diseases in PD-1–deﬁcient mice of different
genetic backgrounds. NOD mice, unlike B6 mice, are well
known for their potential for systemic autoimmunity and
progressive pancreatic -cell–speciﬁc destruction. The ge-
netic components involved in the regulation of PD-1
signaling and the eventual outcome of transgenic PD-L1
expression in -cells may differ between NOD and B6
mice. Although polymorphisms in the PD-1 gene may
explain part of these complicated phenomena, the detailed
mechanism for these strain-dependent variations of pheno-
type are not yet clear (20,21).
PD-L1, in addition to binding to PD-1, has been reported
to interact with a non–PD-1 receptor and to transmit both
costimulatory and apoptotic signals (22). The PD-L1 bind-
ing sites for PD-1 and the unknown receptor are distinct. It
has also been demonstrated that PD-L1 mutants with
impaired PD-1 binding have signiﬁcantly increased co-
stimulatory potential (23). However, the regulation of the
balance for PD-L1 transmitting a negative signal through
PD-1 or a positive signal through the unknown receptor is
not yet clear. The interactions of PD-L1 with PD-1 or the
unknown receptor are distinct, and it is possible that they
compete with each other to inﬂuence the TCR activation
threshold (23). Therefore, it is possible that different
threshold levels of regulation through the PD-1/PD-L1 or
unknown receptor/PD-L1 pathways could lead to the di-
vergent results in NOD and B6 mice. Finally, the differen-
tial levels of expression of transgenic and/or endogenous
PD-L1 in -cells may also contribute to the discrepancy
between these two models. It is possible that in L1C NOD
mice, overexpressed transgenic PD-L1 binds PD-1 and
transduces an inhibitory signal to autoreactive T-cells,
whereas in B6 transgenic mice, overexpressed PD-L1 has a
dominant-negative effect binding to PD-1 but, for some
unknown reason, not transducing a signal.
In our transplantation model, the failure of long-term
graft survival may imply two possibilities. One possible
explanation may be that insulin promoter–driving expres-
sion of PD-L1 was disturbed by the primary nonfunction of
transplanted islets. Another possible explanation is that
transplantation processes trigger strong oxidative stress-
or cytokine-induced apoptosis of transplanted islets,
which cannot be prevented by PD-L1.
It has been well characterized that an imbalance be-
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developing autoimmune diabetes (17). Based on our triple
transgenic model in this study, we demonstrate that the
number and percentage of IFN-–producing (hThy1
)o r
IL-4–producing (mThy1.1
) cells in spleen or PLN in
PD-L1/T1/T2 triple transgenic mice were not different from
those in T1/T2 double transgenic mice (Fig. 5A), suggest-
ing that transgenic PD-L1 in islets does not suppress
systemic IFN-–producing cells or induce IL-4–producing
cells. This result does not support our original idea that the
protective mechanism in L1C mice may be mediated by
“rebalancing” Th1 and Th2 development. However, this
result is consistent with the primary observation from
another group that the numbers of IFN-– or IL-4–produc-
ing cells in spleen and PLN are similar between PD1
/
and control mice (24). However, further analysis of T-cells
inﬁltrating the pancreas revealed that the percentage of
IFN-–producing cells in PD-1
/ mice is much greater
than in normal NOD mice (8,24). This considerable dis-
crepancy in Th1 cell development between L1C and PD-
1
/ mice suggests two possibilities. One possibility is that
both PD-L1– and PD-L2–mediated signaling pathways are
blocked in PD-1
/ NOD mice and this causes the net
effect on Th1 polarization. Alternatively, whereas loss of
function in PD-1 from a very early developmental stage
substantially promotes the development of Th1 cells, a
gain of function and local expression of transgenic PD-L1
insufﬁciently inhibits Th1 polarization and maintains the
systemic Th1/Th2 balance.
Our result also revealed that L1C mice and control
littermates exhibited similar numbers and percentages of
CD4
25
 cells in spleen and PLN (Fig. 5A), suggesting that
transgenic PD-L1 is not likely to increase the population of
Tregs. This is supported by the data from L1C and from
other transgenic lines generated in our laboratory in which
the insulin promoter drives different immunomodulatory
genes, including decoy receptor 3 (13), PD-L2, single-chain
anti–CTLA-4 Fv, or heme oxygenase-1 (S. Shieh, S. Huang,
H.-K.S., unpublished data), where our results suggest that
“local” transgene-mediated protection is not through the
induction of Tregs. These results also suggest that genetic
manipulation of immune responses in an organ-speciﬁc
manner is not likely to induce the systemic development of
Tregs.
The signiﬁcant protection mediated by islet-speciﬁc
PD-L1 expression in L1C mice is consistent with a recent
report that PD-L1
/ NOD mice displayed an aggressive
autoimmunity with a rapid onset of disease and complete
diabetic penetrance (8). Consistent with these results, a
current report also demonstrates that both the insulin-
induced remission in new-onset autoimmune diabetes and
the long-term maintenance of immune tolerance in NOD
mice are highly dependent on the PD-1-PD-L1 pathway
(25). Interestingly, PD-L2
/ mice developed a similar
autoimmune phenotype to NOD littermates (8), consistent
with our observation that transgenic expression of PD-L2
in islets mediates a weaker immunoprotection (C.-J.W.,
H.-K.S., unpublished data) than that observed in L1C mice.
Both of these results support the uniqueness and impor-
tance of the role of PD-L1 in preventing autoimmune
diabetes. A very recent report demonstrates that PD-L1
speciﬁcally interacting with the B7-1 costimulatory mole-
cule suppresses T-cell responses and inhibits cytokine
production (26). These bidirectional inhibitory interac-
tions of PD-L1 to PD-1 and B7-1 provide an additional
dimension to immune network of PD family and further
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noprotection on autoimmune diseases.
It has been reported that engagement of PD-1 and its
ligand results in G0/G1 arrest and inhibits T-cell responses
(7,27), and our study demonstrated that L1C lymphocytes
were less responsive to TCR stimulation. This lymphocyte
arrest may be caused by the interaction of PD-1 and
transgenic PD-L1. PD-1/PD-L1–mediated inhibition can be
overridden by various factors, such as CD28, IL-2, LPS,
CpG, and IL-4 (28,29). The threshold of T-cell activation is
decreased in PD-1
/ lymphocytes (30), consistent with the
increased autoimmune reactivity in PD-1
/ mice (4,5).
The results in our study suggest that local expression of
transgenic PD-L1 in the pancreas of L1C mice, where
autoantigens are highly expressed, inhibits the priming
and clonal expansion of pathogenic lymphocytes at an
early stage, suppressing the production of inﬂammatory
factors and thus providing protection.
Promoting an inhibitory signal through the PD-1/L1
pathway can also be applied as a therapeutic strategy in
allograft transplantation. The ability of the PD-1/L1
pathway to negatively regulate alloimmunity and pro-
mote allograft survival has been demonstrated in vari-
ous transplantation systems, including cardiac (29), skin
(31), and islet transplantation (11). However, enhancing
the PD-1 pathway alone is not enough to completely
ensure graft survival, and combining treatment with
cyclosporine A or CD154 blockade can more efﬁciently
prevent graft rejection (11). Our results with L1C trans-
genic mice are the ﬁrst demonstration of the protective
potential of transgenic PD-L1 in autoimmune diabetes
and provide a theoretical basis for genetic manipulation
of islets for future transplantation.
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